Nelson Advisors: Next Generation Wearable Biosensing - Market Analysis of Sava Technologies’ Series B and Commercial Scaling
Continuous glucose monitoring (CGM) represents one of the most commercially robust sectors within medical technology, transitioning diabetes management from episodic capillary blood testing to continuous, actionable glycemic trend analysis. Despite widespread adoption among insulin-dependent populations, conventional CGM systems remain tethered to subcutaneous filament architectures that penetrate several millimeters into the skin, introducing tissue trauma, biofouling and manufacturing friction.
The closure of a €32.08 million ($36 million) Series B funding round by London based Sava Technologies, anchored by strategic corporate lead Ascensia Diabetes Care, establishes a pivotal moment in the clinical translation of intradermal micro sensor platforms.
By securing €60.6 million ($68 million) in cumulative equity, initiating automated manufacturing scale-up and securing European distribution rights through a major diabetes care commercialisation infrastructure, Sava is positioning its proprietary microneedle based platform to directly challenge the established subcutaneous filament duopoly.
Capitalisation Architecture and Syndicate Composition
Sava Technologies emerged from five years of stealth development in June 2024, founded by Imperial College London bioengineers Renato Circi and Rafaël Michali. The company’s capitalisation strategy reflects rapid institutional backing across consecutive funding rounds, progressing from academic proof of concept validation to high volume commercial production readiness.
Cumulative Capitalisation Summary
Financing Round | Disclosure Date | Capital Secured (EUR / USD) | Lead Investor(s) | Syndicate Participants | Primary Operational Objective |
Seed Round | June 2024 | €7.4M / $8.0M | Balderton Capital, Exor Ventures | SOSV | Prototype de-risking, sensor architecture validation |
Series A | July 2025 | €16.6M / $19.0M | Balderton Capital, Pentland Ventures | Norrsken VC, JamJar Investments, True Global, Exceptional Ventures | Human clinical trials, pilot manufacturing automation |
Series B | October 2026 | €32.08M / $36.0M | Ascensia Diabetes Care | Balderton Capital, Norrsken VC, Simplyhealth Ventures, JamJar Investments, Pentland Ventures | Pivotal clinical trial execution, CE mark clearance, European commercial launch |
Total Capital | 2024–2026 | €60.6M / $68.0M | — | — | Full-scale commercial readiness and clinical translation |
The composition of the Series B syndicate reflects a deliberate convergence of venture growth capital and established corporate medical device capability. Institutional backers such as Balderton Capital, Norrsken VC, and Pentland Ventures participated to fund the long term, multi analyte biosensing capabilities of Sava's modular platform across preventive medicine and digital health.
Concurrently, the strategic equity investment from Ascensia secures immediate commercial distribution rights to a non invasive, high-volume sensor that offsets structural volume declines in traditional finger stick blood glucose monitoring without requiring internal greenfield sensor development.
Commercial Partnership Structure and the Ascensia PHC Ecosystem
The distribution agreement between Sava Technologies and Basel-headquartered Ascensia Diabetes Care establishes an integrated commercial vehicle targeting European healthcare systems. Ascensia operates as a key subsidiary of PHC Holdings Corporation (TYO 6523), a global healthcare enterprise that reported consolidated net sales of JPY 364.4 billion in FY2025 across more than 125 countries.
Ascensia itself maintains direct commercial organisations across 29 national markets and distributes products in more than 90 countries through its established CONTOUR portfolio of blood glucose monitoring hardware and test consumables.
Ascensia's commercialization push follows a major portfolio realignment. Between 2020 and late 2025, Ascensia served as the global commercialisation and distribution partner for Senseonics Holdings' long-term implantable Eversense continuous glucose monitor systems. While technologically distinct, the surgical insertion requirements, mandatory clinical office visits, and sub-fascial removal procedures associated with implantable systems limited rapid adoption within primary care and retail pharmacy distribution.
In September 2025, Senseonics and Ascensia mutually agreed to transfer global sales, marketing, and commercial operations for Eversense 365 directly back to Senseonics. Definitive agreements executed in early 2026 formalised this operational handover, culminating in the complete transfer of European commercial assets by mid-2026.
This transition created an immediate strategic opening within Ascensia’s portfolio. With global blood glucose monitoring revenues experiencing steady erosion from non-invasive continuous monitors, Ascensia required an accessible, user-applied wearable sensor suited for retail pharmacy shelves, clinical prescribing channels, and national reimbursement frameworks. Sava provides a consumer-friendly, self-applied intradermal patch that replicates the user convenience of conventional continuous monitors while introducing a less disruptive form factor.
For Sava, the partnership mitigates the high commercial burn rates typical of early-stage medical device commercialisation. By relying on Ascensia’s established field sales forces, key opinion leader networks, and payer contracting infrastructure across Europe, the startup circumvents the capital intensive task of constructing an independent distribution apparatus.
Intradermal Microsensor Architecture and Biochemical Mechanisms
Commercial continuous glucose monitors, exemplified by the Dexcom G7 and Abbott FreeStyle Libre 3—rely on a flexible enzymatic filament inserted approximately 5 mm to 10 mm beneath the cutaneous surface into subcutaneous adipose tissue using a spring loaded hypodermic needle. Sava’s platform diverges from this mechanism by interrogating the dermal interstitial fluid via an array of micro fabricated sensors that are roughly ten times shorter than traditional filaments, penetrating approximately 0.5 mm to 1.0 mm into the skin.
Dermal Physiology and Biointerface Dynamics
The human cutaneous architecture comprises three primary layers: the non-viable stratum corneum and cellular epidermis (0 to 100 $\mu\text{m}$), the underlying vascularized dermis (0.1 mm to 2.0 mm), and the deep subcutaneous adipose tissue (exceeding 2.0 mm). Conventional continuous monitors bypass the cutaneous barrier entirely to reside in deep subcutaneous fat. Subcutaneous tissue is poorly vascularised relative to the dermis, predisposing sensors to mechanical displacement, local compression artifacts during sleep, and transport lags relative to vascular glucose concentrations.
Deep subcutaneous insertion also elicits an acute foreign body response. The introducer needle inevitably ruptures small venules and capillaries, inducing microvascular hematomas, platelet activation, and localized inflammation. This inflammatory cascade alters local metabolic consumption and generates a fibrous encapsulation capsule over time, which degrades enzymatic diffusion membranes and leads to sensor baseline drift.
Sava avoids these complications by restricting sensor penetration to the upper and mid-dermis. The dermis contains a rich, dense capillary plexus bathed in accessible interstitial fluid that mirrors intravascular glucose fluxes with minimal diffusion delay. Because the micro sensors do not penetrate into deep subcutaneous adipose beds or contact deep somatic pain receptors, sensor application is pain-free and avoids the tissue disruption seen with needle applicators.
Furthermore, shallow dermal penetration minimises insertion trauma and bleeding. Lower insertion site trauma suppresses early inflammatory cytokine release and biofouling, stabilising the enzyme-electrode interface and eliminating the lengthy warm-up calibration periods that have historically challenged subcutaneous continuous monitors.
Comparative Architecture: Dermal Microsensor Array vs. Conventional Subcutaneous CGM
System Parameter | Conventional Subcutaneous CGM (Abbott, Dexcom) | Sava Technologies Intradermal Microsensor | Physiological and Clinical Implications |
Penetration Depth | 5.0 mm to 10.0 mm | ~0.5 mm to 1.0 mm (~10x shorter) | Eliminates adipose insertion; interrogates superficial dermal interstitial fluid. |
Insertion Mechanism | Spring-loaded spring/plunger with steel introducer | Gentle cutaneous patch applicator | Alleviates needle phobia and reduces mechanical tissue trauma during application. |
Sensing Medium | Subcutaneous interstitial fluid | Dermal interstitial fluid | Interrogates fluid closer to dense capillary beds, lowering physiological transport delays. |
Tissue Biofouling Profile | Acute inflammatory cascade and fibrous encapsulation | Reduced tissue disruption and low microhemorrhage | Mitigates enzyme passivation, suppressive drift, and severe sensor baseline loss. |
Validated Continuous Wear | 10 to 15 days | 10 days clinically validated | Resolves early microneedle degradation issues that historically caused failure after 24–48 hours. |
Manufacturing Process | Semi-automated mechanical wire assembly | High-throughput microfabrication and automated lines | Lowers recurring unit production costs at commercial volume. |
Multi Analyte Multiplexing Architecture
Although clinical reimbursement models prioritize glucose measurement, Sava’s core sensing interface functions as an analyte-agnostic, modular electrochemical platform. Dermal interstitial fluid contains an abundant array of small molecules, metabolites, and systemic biomarkers that correlate closely with circulating vascular concentrations.
Sava’s micro electrode array allows individual micro-projections within the same patch substrate to be functionalised with distinct bio recognition elements, such as specific oxidases, dehydrogenases, or ionophores, without analytical cross-talk. By deploying targeted enzyme membranes across isolated working electrodes, the platform can monitor multiple analytes simultaneously:
Continuous measurement of $\beta$-hydroxybutyrate provides an early warning system for diabetic ketoacidosis (DKA) in patients with Type 1 diabetes, while serving nutritional monitoring applications for individuals on ketogenic diets.
Real-time profiling of dermal lactate informs athletic endurance conditioning, anaerobic threshold identification, and critical inpatient detection of tissue hypoperfusion or lactic acidosis.
Dynamic tracking of cortisol enables continuous assessment of the hypothalamic-pituitary-adrenal axis, addressing chronic metabolic stress, adrenal disorders, and circadian rhythm variations.
Electrochemical potentiometric tracking of sodium and related electrolytes supports ongoing assessment of cellular hydration status and renal clearance.
Clinical Validation and the Regulatory Path to Non Adjunctive Approval
A key historical limitation of microneedle-based electrochemical biosensors has been signal instability. Early-generation microneedles frequently suffered from sensitivity loss within 24 to 48 hours of application due to epidermal sloughing, pore healing dynamics, mechanical displacement, and bio-interfacial passivation. In February 2026, Sava announced clinical results demonstrating that its proprietary intradermal microsensor maintains operational stability over extended wear periods.
Oxford and Cambridge Multi Centre Clinical Trial Outcomes
The multi-center trial enrolled 46 adult participants diagnosed with Type 1 diabetes and insulin-dependent Type 2 diabetes across dedicated clinical investigation facilities in Oxford and Cambridge. The protocol evaluated Sava’s microsensor in a direct head-to-head comparison with a globally leading commercial continuous glucose monitor, benchmarking both systems against the clinical laboratory reference standard, the Yellow Springs Instrument (YSI 2300 STAT Plus Glucose Analyzer).
The trial confirmed continuous, stable access to dermal interstitial fluid over a full 10-day wearing period across the study cohort. Analytical accuracy was comparable to the commercial comparator device, with the micro sensor demonstrating an overall Mean Absolute Relative Difference (MARD) within approximately 0.8 percentage points of the commercial system relative to the reference standard.
Furthermore, the sensor exhibited low electrochemical drift, recording an accuracy degradation of only approximately 1.5 percentage points across the 10-day wearing window. These data confirmed that micro fabricated dermal sensors can maintain signal stability over multi-day wear profiles without premature biofouling or operational failure.
Clinical Validation and Regulatory Milestones
Milestone Parameter | Verified Clinical Metric / Regulatory Target | Strategic and Regulatory Significance |
Trial Cohort Characteristics | 46 subjects (Type 1 and insulin-dependent Type 2) | Verifies sensor tracking across wide glycaemic excursions and insulin challenges. |
Investigation Sites | Oxford and Cambridge clinical research centres, UK | Independent academic clinical environment providing rigorous comparator validation. |
Validated Wear Duration | 10 days continuous monitoring | Solves early microneedle degradation issues and matches incumbent 10-day products. |
Comparative MARD Delta | ~0.8 percentage points variance vs. market leader | Confirms measurement parity with leading commercial continuous glucose monitors. |
10-Day Signal Stability | ~1.5 percentage points drift across duration | Validates the biostability of the enzyme-electrode membrane in human dermal tissue. |
Target Regulatory Approval | CE mark under EU MDR 2017/745 Class IIb | Required for lawful commercialization and distribution within European Union markets. |
Intended Clinical Label | Non-adjunctive use indication | Permits direct insulin dosing decisions without confirmatory capillary fingerstick tests. |
Projected Launch Window | 18 to 24 months (Targeting 2027–2028 deployment) | Defines the timeline for pivotal trial execution, audit review, and commercial supply rollout. |
European MDR Conformity and the Non Adjunctive Dosing Standard
The Series B capital is allocated to execute a formal pivotal trial required for European Medical Device Regulation (EU MDR 2017/745) Class IIb certification. Sava is explicitly seeking a non-adjunctive use label from European Notified Bodies.
The distinction between adjunctive and non-adjunctive regulatory clearances represents a critical commercial boundary in diabetes care. Adjunctive systems require patients to corroborate sensor readings with a capillary finger stick test prior to calculating and administering corrective insulin boluses, effectively relegating the wearable to a secondary trend monitor.
Conversely, non-adjunctive clearance permits patients to calculate insulin doses and make active therapeutic decisions directly from the device's numerical outputs and trend vectors. To secure non-adjunctive designation, the European Notified Body requires demonstrated sensor accuracy within acute hypoglycemic ranges (<70\text{ mg/dL}), a tightly bound Consensus Error Grid distribution (consistently exceeding 99% of paired values within clinical Zones A and B), and continuous on-sensor diagnostic firmware capable of alerting users to electrode detachment or sensor anomalies.
Sava anticipates an 18 to 24-month regulatory timeline to complete the multi-centre pivotal trial, submit its technical documentation under EU MDR guidelines, obtain CE mark approval, and launch commercial supply through Ascensia. The device remains in an investigational phase and has not yet obtained regulatory marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) or the United States Food and Drug Administration (FDA).
Corporate Origins, Automated Microfabrication and Executive Leadership
Sava Technologies was founded in 2019 by biomedical engineers Renato Circi and Rafaël Michali, who developed the company's early sensor concepts during their academic tenures at Imperial College London. Their academic environment maintained deep historical ties to early biosensor breakthroughs, including research groups that contributed to the chemical and physical foundation of commercial glucose test strips.
Operating in stealth for five years, Circi and Michali adopted an engineering first development model. The founders avoided consumer software "Minimum Viable Product" (MVP) practices, recognising that medical devices require high-yield automated manufacturing processes and strict tolerances before entering clinical validation. Medicalmgrade micro fabrication requires exact enzyme deposition, uniform electrode geometries, and stable microfluidic packaging.
The Series B financing will support the transition of Sava's UK facilities from pilot-scale assembly to fully automated production lines capable of supplying European demand. To guide this transition, Sava expanded its London-based staff beyond 60 personnel, drawing specialised technical and operational talent from established industry leaders including Abbott and Dexcom.
In May 2026, Sava appointed John Bernard, previously a commercial leader at Dexcom EMEA, as Chief Commercial Officer. Bernard's background in scaling Dexcom’s footprint across European health systems complements Ascensia’s retail presence, supporting Sava's launch and market access initiatives.
Competitive Landscape and Macroeconomic Dynamics
The global continuous glucose monitoring sector is expanding rapidly, supported by growing clinical evidence, expanding insurance coverage for non-insulin-treated Type 2 diabetes and interest in metabolic health tracking among consumers.
Epidemiological estimates from the International Diabetes Federation (IDF) show that 589 million adults are currently living with diabetes globally, a figure projected to rise to 853 million by 2050. However, only an estimated 12 million individuals currently utilise continuous glucose monitors worldwide.
Market data from Fortune Business Insights values the global continuous glucose monitor market at $13.86 billion in 2025, projecting expansion to $33.61 billion by 2034 at a compound annual growth rate of 10.1%. The wide gap between the 12 million current users and the broader global patient population underscores persistent access barriers, including high sensor costs, skin irritation, needle aversion and restrictive payer reimbursement criteria for non-insulin-dependent populations.
Competitive Positioning Across Emerging Continuous Biosensing Platforms
Platform / Manufacturer | Sensor Technology | Target Indication and Audience | Regulatory Status | Commercial Channel & Distribution |
Abbott FreeStyle Libre 3 / Rio | Subcutaneous enzymatic wire (5–10 mm) | Intensive insulin users; non-insulin T2D (Rio) | Fully approved: CE Mark, US FDA Clearance | Direct pharmacy, retail distribution, global healthcare reimbursement |
Dexcom G7 / Stelo | Subcutaneous enzymatic wire (5–10 mm) | Intensive insulin management; non-insulin T2D wellness (Stelo) | Fully approved: CE Mark, US FDA Clearance | Prescribed DME/pharmacy formulary; direct-to-consumer OTC |
Abbott Libre Duo | Subcutaneous dual-filament array | Dual glucose and ketone monitoring for DKA prevention | FDA Authorized (10-day wear duration) | Clinical endocrinology and diabetes hospital/pharmacy networks |
Biolinq Shine | Intradermal microneedle array with LED | Adults with Type 2 diabetes not using insulin | FDA De Novo Clearance (Time-in-range indicator) | Specialized retail and consumer metabolic wellness channels |
Sava Technologies Platform | Intradermal electrochemical microsensors (~0.5–1.0 mm) | Intensive Type 1 & Type 2 diabetes; future multi-analyte health | Investigational; Targeting non-adjunctive CE Mark in 18–24 mo | Exclusive European distribution via Ascensia/PHC Group |
The entry of next generation continuous biosensors highlights distinct regulatory and commercial paths. In October 2025, San Diego-based Biolinq obtained FDA De Novo clearance for Biolinq Shine, an intradermal microneedle device featuring integrated LED visual feedback, supported by a $100 million venture round.
However, Biolinq Shine received marketing clearance as an autonomous time in range indicator specifically for adults with Type 2 diabetes not on insulin, rather than as a numerical continuous monitor. The device provides qualitative range status rather than dynamic numerical values or trend vectors, distinguishing its clinical positioning from intensive insulin-dosing applications.
Incumbents are also expanding their technological footprints. Abbott secured regulatory authorization for the Libre Duo, a two in one biowearable that simultaneously measures glucose and ketone levels over a 10 day wear duration using standard subcutaneous filament technology. Dexcom has similarly expanded into consumer metabolic health with the launch of its Stelo platform for non-insulin users, alongside 15-day sensor extensions for the Dexcom G7.
Sava differentiates itself by targeting a medical-grade, numerical continuous monitor with non-adjunctive insulin dosing indications, built on an intradermal microneedle array. By securing an established European commercialisation partner in Ascensia, Sava avoids the direct distribution challenges that have slowed earlier medical device entrants.
Strategic Synthesis and Outlook
Sava Technologies’ €32.08 million Series B financing and commercial alliance with Ascensia Diabetes Care represent a structured model for transitioning academic biosensing innovation into commercial execution. By combining proprietary microfabrication techniques with an established commercial distribution network, Sava has addressed key early-stage risks in continuous monitoring.
Over the coming 18 to 24 months, Sava’s primary test centres on execution across three operational priorities:
First, scaling high volume manufacturing lines requires precise enzyme deposition and structural consistency across millions of microneedle arrays. Transitioning from controlled batch runs to high throughput commercial volumes without yield loss remains a key milestone for device reliability.
Second, securing non-adjunctive regulatory labeling under EU MDR demands high statistical accuracy during severe hypoglycemic excursions. Demonstrating that dermal interstitial fluid remains analytically reliable when peripheral capillary vasoconstriction occurs during low blood sugar events will be essential for the pivotal clinical trial.
Third, while the platform's multi-analyte roadmap (ketones, lactate, and cortisol) offers significant commercial potential, execution in the near term will depend on commercial adoption within core diabetes care.
If Sava successfully completes its pivotal clinical studies and secures non adjunctive CE approval, Ascensia’s retail and clinical networks will provide immediate access to European markets. This integration positions intradermal microsensors to challenge conventional subcutaneous filaments, offering an accessible, pain-free alternative for individuals living with diabetes.
Nelson Advisors > European Healthcare Technology Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions for European HealthTech, MedTech, Digital Health, Healthcare IT, Healthcare AI companies in the Lower to Mid Market ranging from $25M to $250M EV. www.nelsonadvisors.co.uk
Healthcare.Digital is the Google News approved HealthTech and MedTech Thought Leadership platform for Nelson Advisors, positioning them as a specialised authority on European Healthcare Technology M&A and strategic corporate development. https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Healthcare.Digital serves as a research platform for Nelson Advisors’ perspectives on deals, valuations and structural shifts reshaping Global Digital Health, MedTech, Healthcare AI and Health IT. https://www.healthcare.digital
Nelson Advisors is one of Europe's leading mergers and acquisitions advisory firms, exclusively dedicated to the dynamic and rapidly evolving healthcare technology sector. With a deep understanding of market dynamics and technological advancements, they empower innovative HealthTech companies and strategic investors to navigate complex transactions and achieve their growth ambitions. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #Genomics
Nelson Advisors
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ Events in 2026
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
HealthInvestor Healthcare Summit > September 2026, London, UK
World Health Summit 2026 > October 2026, Berlin, Germany
HLTH USA 2026 > October 2026, USA
Global Health Exhibition 2026 > October 2026, Riyadh, Saudi Arabia
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Leaders in Health Summit 2026 > November 2026, London, UK
Venture Capital World Summit > December 2026, Toronto, Canada
Meet Nelson Advisors @ Events in 2027
Digital Health Rewired > March 2027 > Birmingham, UK
Barclays Health Elevate > March 2027, London, UK
NHS ConfedExpo > June 2027 > Manchester, UK
HLTH Europe > June 2027, Amsterdam, Netherlands
Comments